A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
Authors:
Open Access
- 11 November 2022
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 24 (2) , e65-e68
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialJournal of Clinical Oncology, 2022
- Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II TrialJournal of Clinical Oncology, 2021
- Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung CancerNew England Journal of Medicine, 2021
- Abstract 1472: Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical needCancer Research, 2021
- Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLCCritical Reviews in Oncology/Hematology, 2020
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityCancer Cell, 2019
- Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid CancersThe Oncologist, 2019
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancerNature Medicine, 2018
- Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicitiesAsia-Pacific Journal of Clinical Oncology, 2017
- Activating HER2 mutations as emerging targets in multiple solid cancersESMO Open, 2017